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Abstract
Background—Archived formalin-fixed, paraffin-embedded specimens represent an important
resource for pharmacogenomic analysis in retrospective clinical studies but the quality of results
from formalin-fixed, paraffin-embedded samples is of concern due to the fact of the degradation of
DNAs and RNAs from formalin-fixed, paraffin-embedded tissues.
Methods—In the present study, we used DNA from fresh frozen as well as formalin-fixed, paraffin-
embedded tumor to detect copy-number changes in colorectal cancer, and our data shows that
formalin-fixed, paraffin-embedded DNAs were able to deliver reliable copy-number data, and that
quantitative PCR had the ability to detect copy-number changes from deletion to amplification, with
high concordance of copy-number calls among formalin-fixed, paraffin-embedded and frozen DNAs.
Results—The amplification of topoisomerase I and deletion of thymidylate synthase were found
in 23% (12/52) and 27% (14/52) of colorectal cancers, but EGF receptor amplification was not
common (5/52, < 10%). Among 52 colorectal cancers, 31 tumors were both topoisomerase I and
thymidylate synthase diploid, which may have a worse outcome for tumor chemotherapy; and there
were five tumors with favorable genomics (topoisomerase I amplification and thymidylate synthase
deletion). Furthermore, topoisomerase I-amplified tumors had a two-times higher RNA level and a
nearly twofold higher protein expression level than did the diploid tumors (p < 0.001 and 0.01,
respectively), but there were no correlations between copy-number status and RNA or protein level
for thymidylate synthase.
Conclusions—Our study suggests a potential pharmacogenomic influence of topoisomerase I
copy-number alteration on its RNA/protein expressions, which could be reflected on tumor response
to chemotherapy in human colorectal cancer.
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In the post-genomic era, the study of human genetic variation at the DNA level constitutes a
major challenge and holds promises to benefit patients through identification of those
significant variants in clinical settings [1,2]. Recent molecular cytogenetic analysis suggests
that alteration in DNA copy number can be a mechanism for variability in tumor sensitivity to
anticancer therapy [3,4], and most studies on DNA copy-number changes have been using
unfixed fresh-frozen specimens that give high quality DNA samples and deliver reliable copy-
number data for downstream analysis. Such tumor sets are often small and lack clinical
annotation, whereas formalin-fixed, paraffin-embedded (FFPE) materials are abundant [5,6].
FFPE specimens represent a source of archived and morphologically defined disease-specific
biological material for which extensive clinical data are often available. Extraction of DNA
and RNA from these specimens provides an opportunity for retrospective analysis using
molecular techniques such as microarrays, cytogenetic hybridizations, or real-time quantitative
PCR (qPCR) that may accelerate the discovery of associations among genomic changes or
gene-expression signatures and treatment outcomes.
A barrier to the analysis of FFPE samples is that DNA and RNA extracted from FFPE tissues
is often significantly degraded to an average fragment length around 300−400 bp for DNA and
200 bp for RNA [7,8]. While researchers using PCR-based approaches to analyze gene copy-
number changes and gene-expression levels in FFPE have been able to successfully obtain data
[9,10], the reliability and accuracy of results from FFPE DNAs/RNAs would become the major
concern. In the present study, we have used the fresh frozen as well as FFPE DNAs to detect
the copy-number changes of two key genes (see below) in colorectal cancer. By comparing
the results from matched fresh-frozen and FFPE DNAs, we will be able to provide evidence
for the accuracy and reliability of the qPCR in detection of DNA copy-number alterations in
the FFPE DNAs.
In human colorectal cancer, chromosome 20 gain and 18 loss are common, including the
TOP1 and TYMS genes [11], the key target genes for irinotecan- and 5-fluorouracil-based
chemo-therapy, respectively. The present study assessed DNA copy-number changes and
alterations in RNA and protein expressions for TOP1 and TYMS in order to establish potential
associations between genomic DNA copy-number changes and phenotypic RNA/protein
profiles as a preliminary pharmacogenomic assessment.
Materials & methods
Patients & samples
Tumor specimens and paired normal colon tissues used in this study were from 52 Dukes’ C
(stage III) colorectal cancer patients (29 male/23 female, age range: 32−96 [median: 69.5]
years), who had not received any chemotherapeutic agents before surgery. Samples were snap
frozen in liquid nitrogen immediately after surgery and stored at −80°C. At the same time,
FFPE tissues from these patients and from 18 glioma patients were also included in this study.
The tumor specimens selected for DNA and RNA isolation had high tumor cellularities. Written
informed consent was obtained from all patients to bank tumor tissue and to perform genomic
analysis. This study was approved by the Washington University Human Subjects Committee.
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All DNA was extracted at the Siteman Cancer Center Tissue Procurement Core in Barnes-
Jewish Hospital (MO, USA). Archival tissue blocks included gliomas, colorectal tumors, and
normal colon tissues; and fresh-frozen tissues were colorectal tumors and matched normal
colons. Frozen tissues were first embedded in OCT blocks, and then one 50-μ section from the
block was placed in ALT buffer (included in QIAamp® kit) and proteinase K was added in
the buffer for an overnight digestion at 56°C. A 50-μ section was punched out from FFPE
blocks and subjected to standard deparaffinization procedures and proteinase K digestion
overnight. After tissue digestion, the fresh DNAs were isolated according to the protocol with
QIAamp DNA Mini Kit from Qiagen (CA, USA); and the FFPE DNAs were extracted
following the instructions for DNA isolation with the phenol:chloroform:isoamyl alcohol
(25:24:1) solution from Ambion, Inc. (TX, USA). DNA quality was assessed based on the
optical density (OD) 260/280 ratio and 1% agarose gel electrophoresis.
Quantitative PCR
Real-time quantitative PCR was employed to detect gene copy-number changes and RNA
levels. Briefly, 10-μl reaction mixture for qPCR was composed of 5 μl of 2× TaqMan®
universal PCR master mix (Applied Biosystems Inc. – ABI), 5 μl of primer and probe mix (600
nM each forward and reverse primers, 200 nM specific TaqMan probe at final concentration),
and 10 ng of DNA/cDNA (dried in wells of PCR plate overnight before adding the reaction
mixture). All real-time PCR assays were performed in triplicate on an ABI PRISM 7900HT
Sequence Detector System (ABI) and followed the program: 50°C for 2 min, 95°C for 10 min,
and 40 cycles of both 15 s at 95°C and 60 s at 60°C. Primers and TaqMan probes used in this
study were designed using Primer Express version 1.5 (ABI) and are displayed in Table 1.
Determination of RNA levels was performed according to our previous studies [12,13].
Determination of DNA copy-number changes
In this study, we detected copy-number changes for three genes: TOP1, TYMS and EGFR. Two
internal reference genes (a house keeping gene: ACTB and a genomic repeat: LINE1 [4]) were
used to normalize the DNA input between individual DNA samples, and the normal DNA
samples were used to scale the copy number by diploid genome. For each gene (both reference
and target genes), a standard curve was established to calculate the raw copy value (RCV) for
all DNA samples based on computed tomography (CT) values generated by the 7900HT. The
ratio between target and reference genes for each DNA sample (including tumor and normal)
was resolved by two RCVs: one for target gene and the other for reference gene in a same DNA
sample. Finally, the copy number for a specific gene in a specific DNA sample was the product
of the overall ratio between two target-reference ratios from tumor and normal DNAs
multiplied by 2, and then was presented in integer by rounding up the product.
Immunohistochemical staining
The protein expression of TOP1 and TYMS was determined on customized tissue microarray
by immunohistochemical staining as previously described [14], and the score of 0, 1, 2 or 3
was graded to each sample based on their intensity and number of positive cells. The final score
for a sample was average of replicate spots on the arrays.
Statistical analysis
Statistical analyses were performed with the software STATISTICA (StatSoft, Inc., OK, USA).
Significance of difference in RNA and protein levels between copy-number statuses was
evaluated by the Mann–Whitney U test. The significance level was set at p < 0.05.
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Most of FFPE DNAs were able to deliver reliable copy-number data
In this study, 46 of 52 tumors had matched frozen and FFPE DNAs. All 52 frozen DNAs and
34 of 46 FFPE DNAs were able to deliver reliable copy-number data with qPCR assays. A
total of 26% (12/46) of the FFPE DNAs had the CT values greater than 35 even after 40 cycles,
which was excluded for further analysis. In addition, using the same amount of DNA (10 ng),
the tumor FFPE DNAs were tenfold lower than the tumor fresh DNAs in RCVs for ACTB,
TOP1 and TYMS, and over 20-fold lower in RCV for LINE1 (Figure 1). The normal tissue
FFPE DNAs had a similar decline in RCV. This reflects the fact that the FFPE DNAs have
been heavily fragmented (the size around 300 bp) and much less fragments with the whole
range of qPCR amplicons are available in the reactions even though the input amount is same.
Particularly, because of the large copy number of LINE1 (over 50,000 copies per diploid cell)
in the genome, which makes LINE1 having more chances to be fragmented, it is not surprising
that LINE1 had a bigger RCV drop than diploid genes in the FFPE DNAs. On the other hand,
the target-reference RCV ratio in tumor FFPE DNAs was shifted down by 37% than that in
tumor fresh DNAs for both TOP1 and TYMS when normalizing to ACTB, but it was shifted
up by approximately 130% over tumor fresh DNAs for these two genes when normalizing to
LINE1 (Figure 2). The normal FFPE DNAs had a similar shift in target-reference RCV ratio.
This phenomenon warns the requirement of using normal FFPE DNAs to scale tumor FFPE
DNAs but not using fresh normal tissue DNAs in order to calculate the final copy-number
value per diploid genome [15,16].
The qPCR gave good prediction for EGFR copy-number with wide-range increases
A previous study from our collaborate group has identified EGFR copy-number changes by
fluorescence in situ hybridization (FISH) on slides from FFPE blocks of glioma patients [17].
We selected 18 tumors from that study, of which six tumors from each of three categories in
EGFR copy-number status (amplification, polysomy, normal) were included. Using LINE1 as
reference gene and normal colon FFPE DNAs as diploid control, the qPCR reliably detected
EGFR amplification and normal copy-number in the FFPE DNAs of gliomas, with a wide
range of copy-number increases from 20 to 113 copies per diploid cell, which perfectly falls
into EGFR-amplified category of gliomas identified by FISH (Figure 3). Detection of EGFR-
polysomy tumors seemed a bit underestimated by the qPCR. Four of the six polysomy tumors
were shown 3−4 copies of EGFR and another two polysomy tumors were identified as ‘normal
copy-number’. The reason for this underestimation could be dilution of the EGFR copy number
in the polysomy tumor cells by coexist diploid normal cells. This is a merit of FISH over qPCR
in detection of polysomy tumors [18].
qPCR had good prediction for TOP1 & TYMS copy number with small-range changes
The qPCR had been done for detection of TOP1 and TYMS copy-number changes both in fresh
and FFPE DNAs from the colorectal cancer patients. With one discrepancy (2 copies in FFPE
but 1 copy in fresh DNAs [copy-number product 1.59 vs 1.33] for a tumor referenced by
ACTB), the copy-number calls for TOP1 and TYMS in the FFPE DNAs were highly concordant
to the changes in the fresh DNAs for the same individuals (Figure 4), in both cases where either
LINE1 or ACTB was used as internal reference. These copy-number changes were small, with
a range from 1 to 2 copies for TYMS, and 2−4 copies for TOP1. This indicates that the qPCR
has the ability to detect low copy-number changes in FFPE DNAs as well as fresh DNAs, and
the FFPE DNA can be a reliable resource for copy-number study, especially for association
studies where the treatment and patient outcome data as well as archived pre- and post-therapy
specimens are available.
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Amplification of TOP1 & deletion of TYMS were found in 23 and 27% of untreated colorectal
cancers, but EGFR amplification was not common
TOP1 is on chromosome 20q and TYMS on chromosome 18p, which are hot spots for genetic
aberrations in colorectal cancers. Rooney et al. have reported that ZNF217 is amplified by 3
−13 copies in 61% of Dukes’ A-C colorectal cancers and this gene is within the chromosome
20q13.2, a region which contains also TOP1 and has been previously shown to be highly
amplified in colorectal cancer by comparative genomic hybridization (CGH) [19]. Our results
in fresh DNAs showed that 23% (12/52) of the Dukes’ C-only colorectal tumors were amplified
for TOP1 with 3 or 4 copies (either LINE1 or ACTB used as internal reference) and these tumor
specimens were taken before chemotherapy. The differential rate of TOP1 amplification
between the two studies could be due to tumor stage, treatment, and/or different qPCR
approaches (selection of reference gene and, simplex or multiplex reaction). On the other hand,
Wang et al. [4] have shown that TYMS can acquire resistance to 5-fluorouracil treatment due
to gene amplification after chemotherapy. Our data from fresh DNAs indicated that there was
deletion of TYMS in 27% (14/52) of untreated colorectal cancers and no tumors in our study
showed any amplification for TYMS (either LINE1 or ACTB as internal reference). A previous
study using traditional CGH method [11] showed that the chromosome 18p was frequently lost
in colorectal tumors (20.7%). In addition, 31 tumors were both TOP1 and TYMS diploid, which
may have a worse outcome for tumor chemotherapy; and there were five tumors with favorable
genomics (TOP1 amplification/TYMS deletion). The EGFR amplification was not common in
colorectal cancers, and only less than 10% (5/52) of tumors had EGFR-amplified with a copy
number of 3 in this study.
There were positive associations between copy number & RNA or protein level for TOP1 but
not for TYMS
The RNA data for TOP1 and TYMS were published in our previous studies [12,13]. The median
TOP1 RNA level in amplified tumors was two-times higher than that in diploid tumors (p <
0.001). But there was no significant difference in the RNA level between TYMS diploid and
deleted tumors (Figure 5A). Again, TOP1-amplified tumors had a higher protein expression
than did diploid tumors (median score 1.8 versus 1.0; p < 0.01). However, there was no
significant difference in the protein expression between TYMS deleted and diploid tumors
(Figure 5B). These results implicate that the TOP1 amplification has functional significance
that may contribute to variable responses of cancer patients to TOP1-targeting drugs. However,
the significance of TYMS deletion in naive tumors remains unclear and needs further study.
Our study suggests a potential pharmacogenomic influence of TOP1 copy-number alteration
on its RNA/protein expressions, which could be reflected on tumor response to chemotherapy
in human colorectal cancer.
Executive summary
• Archived formalin-fixed, paraffin-embedded (FFPE) specimens represent an
important resource for pharmacogenomic analysis in retrospective clinical studies
but the quality of results from FFPE samples is of concern due to the fact of the
degradation of DNAs and RNAs from FFPE tissues.
• FFPE DNAs was able to deliver reliable copy-number data and quantitative PCR
had the ability to detect copy-number changes from deletion to amplifications,
with high concordance of copy-number calls among FFPE and frozen DNAs.
• Amplification of topoisomerase I (TOP1) and deletion of thymidylate synthase
(TYMS) were found in 23 and 27% of untreated colorectal cancers, and TOP1-
amplified tumors had a twofold higher RNA level and a nearly twofold higher
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protein level than did the diploid tumors, but no any correlation was observed
between copy-number status and RNA or protein level for TYMS in this study.
• Our study suggests a potential pharmacogenomic influence of TOP1 copy-number
alteration on its RNA/protein expressions, which could be reflected on tumor
response to chemotherapy in human colorectal cancer.
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The same 10-ng DNAs from the FFPE tissues had much lower RCV values in both normal
colon (A) and tumor (B) samples than that from the fresh tissues.
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The target-reference RCV ratios from the FFPE DNAs were shifted down and up in both normal
colon (A) and tumor (B) samples when compared with that from the fresh DNAs and
normalized to ACTB and LINE1, respectively.
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The qPCR reliably detected wide-ranged EGFR amplification defined by FISH in 18 human
gliomas, and compromised a bit in detection of EGFR polysomy tumors likely due to dilution
of the copy-number in polysomy tumor cells by co-existing diploid normal cells.
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Data plots demonstrated good prediction by qPCR for TOP1 and TYMS copy-number changes
between the FFPE and fresh DNAs either normalized by ACTB (A) or LINE1 (B).
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Correlations were observed between DNA copy number and RNA (A) or protein (B) levels
for TOP1, but not for TYMS in 52 colorectal cancer patients.
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Table 1
Primer and probe sequence for DNA copy-number analysis in qPCR assay.
Gene symbol Oligo Sequence Amplicon size (bp)
ACTB Forward CAGCCATGTACGTTGCTATCCA 82
Reverse TCACCGGAGTCCATCACGAT
TaqMan® probe TGTGCTATCCCTGTACGCCTCTGGCC
LINE1 Forward TTGCGGCATTATTCACAATAGC 83
Reverse GTGCCACATTTTCTTAATCCAGTCT
TaqMan probe TGGAACCAACCCAAATGTCCAACAATGA
TOP1 Forward GGCGAGTGAATCTAAGGATAATGAA 97
Reverse TGGATATCTTAAAGGGTACAGCGAA
TaqMan probe TCAGTGACTGAAACCATTTTCCCATCATCC
TYMS Forward GCCTCGGTGTGCCTTTCA 65
Reverse CGTGATGTGCGCAATCATG
TaqMan probe CATCGCCAGCTACGCCCTGCTC
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